The Commonwealth Fund
13
1
1
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
18%
2 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming
Role: collaborator
Using Digital Health, Financial Incentives, and Community Health Worker Support to Change Health Behavior
Role: collaborator
Assisting Low-Income Families at Pediatric Well-Child Care Visits
Role: collaborator
Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer
Role: collaborator
Medication Errors and Adverse Drug Events (ADEs) in Ambulatory Pediatrics
Role: collaborator
Evaluating the Impact on Quality and Costs of Regional Clinical Data Exchange Programs in New York State
Role: collaborator
Evaluating the Effects of EHRs, P4P and Medical Home Redesign in the Hudson Valley
Role: collaborator
Remote Simultaneous Medical Interpreting and Medical Outcomes
Role: collaborator
Adherence, Improvement Measure (AIM) System
Role: collaborator
Improving Diabetes Efforts Across Language and Literacy (IDEALL)
Role: collaborator
EEG Studies of Sensory Processing in Autistic Children
Role: collaborator
Newborn Health Information Study
Role: collaborator
Improving the Outpatient Referral Process With Electronic Communications
Role: collaborator
All 13 trials loaded